Merck KGaA to Close Merck Serono Site in Geneva, Cut Jobs

Merck KGaA plans to close the Geneva headquarters of its Serono unit, five years after buying Europe’s biggest biotechnology company for about $13.3 billion to expand a drug business that has since faced development and regulatory setbacks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.